Q2 2026 revenue rose to €185.1M (from €175.4M) with organic growth of 5.9%. Profitability improved: EBITDA excluding non-recurring items increased to €17.6M (from €14.6M) and the EBITDA margin expanded to 9.5% (from 8.3%), while EBIT turned to €6.6M (from -€6.1M) and net debt/EBITDA improved to 3.4 (from 4.3). However, operating cash flow declined to €9.1M (from €16.1M), partly offsetting the earnings improvement.
This reads as a self-help inflection rather than a growth acceleration story. The equity-relevant signal is the combination of positive EBIT and lower leverage: that usually tightens the credit spread first, then allows multiple expansion if management can prove the margin step-up is not just mix or timing. In the next 1-3 months, the stock should trade less on revenue growth and more on whether cash generation catches up to accounting profit.
The main caution is quality of earnings. Operating cash flow lagging EBITDA suggests working-capital absorption or capex pressure, which can mute any rerating even if reported margins improve. If that gap persists into the next print, the market will likely keep this in the "levered cyclical" bucket, where upside is capped by refinancing sensitivity and rate exposure.
Contrarian take: consensus may be underappreciating how much a move from leverage drift to leverage improvement can change the equity narrative for a mid-cap balance-sheet story. But the move is only durable if net debt/EBITDA keeps moving toward sub-3x and FCF turns reliably positive; otherwise this is a tactical bounce, not a structural de-risking. The thesis is falsified if the next quarter shows weaker organic growth, another cash conversion miss, or any guidance that implies margin normalization was temporary.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.20